Latest Reserves News

Volt Group (ASX: VPR) is set to repurchase up to 5% of its shares over 12 months starting 16 September 2026, aiming to optimise capital structure without requiring shareholder approval.

Capstone Copper has boosted its Atacama presence by acquiring the San Pietro copper project, adding 16,000 hectares and nearly half a billion tonnes of inferred resources to its Mantoverde-Santo Domingo district.

McLaren Minerals has reported its best assay batch yet from the 2026 drilling program at the McLaren Titanium Project, with heavy mineral grades climbing to 5.44% from surface across 1,199 metres.

St Barbara Limited has declared a fully franked dividend and is progressing construction and exploration across its New Simberi and Nova Scotia gold projects, supported by a strong cash position and no debt.

Australian Bond Exchange Holdings (ASX: ABE) reported a 47% revenue increase to $3.55 million for FY26, cutting its loss after tax by nearly two-thirds to $1.51 million amid ongoing going concern uncertainty.

Thorney Opportunities Ltd swung to a $4.44 million loss before tax in FY2026, weighed down by unrealised investment losses, yet increased its final dividend and pressed on with share buybacks.

Cycliq Group Limited reported a 20.7% revenue decline to AUD 3.79 million for FY2026, but reduced its net loss by 83% to AUD 85,897, driven by disciplined cost control and strategic platform investments.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

Infotrust Ltd (ASX: ITS) reported a 9.8% rise in FY26 revenue to $64.1 million, powered by a strategic pivot to cyber security. The company exited its Cloud segment, repaid all bank debt, and acquired Catalyst Cyber to boost federal market presence, positioning for profitable growth in FY27.

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.

NOVONIX Limited posted a $24.6 million half-year loss while delivering a critical synthetic graphite sample to Panasonic and reaffirming a 2027 production start. The company raised $21.7 million to fund its North American battery materials expansion amid ongoing U.S. trade and policy developments.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.